Antibody Information

General Information of This Antibody

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

CMD-193 [Terminated in phase 1]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Complete Remission (CR)	0.00%
Patients Enrolled	Patients with advanced tumours expressing the Lewis-Y antigen.
Administration Dosage	111-In-CMD-193 iv then 1.00 mg/m^2, 2.60 mg/m^2 iv of CMD-193.
*Related Clinical Trial*
NCT Number	NCT00293215	Clinical Status	Phase 1
Clinical Description	Biodistribution study of cmd-193 in patients with advanced tumours expressing the LEWIS-Y antigen.
Experiment 2 Reporting the Activity Date of This ADC				[2]
Patients Enrolled	Patients with advanced malignant tumors.
Administration Dosage	CMD-193 iv.
*Related Clinical Trial*
NCT Number	NCT00257881	Clinical Status	Phase 1
Clinical Description	Phase 1 biodistribution study of 111-indium-CMD-193 in patients with advanced tumours expressing the LEWIS-Y antigen.
Experiment 3 Reporting the Activity Date of This ADC				[3]
Patients Enrolled	Patients with advanced malignant tumors.
Administration Dosage	CMD-193 iv.
*Related Clinical Trial*
NCT Number	NCT00161642	Clinical Status	Phase 1
Clinical Description	Phase 1 dose-escalation study of intravenous CMD-193 in subjects with advanced malignant solid tumors.

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.00% (Day 100)	Positive Lewis-Y expression (Lewis-Y +++/++)
Method Description	hu3S193-CalichDMH (4 ug) induces efficient tumor cell killing in cell line-derived models of PV-1 cells with CD28 expression.
In Vivo Model	N193 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

References

Ref 1	Phase I Biodistribution Study of 111-Indium-CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen
Ref 2	Phase 1 Dose-Escalation Study of Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors
Ref 3	A Phase 1 Dose Escalation Study of CMD-193 in Subjects With Advanced Malignant Tumors.
Ref 4	Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts. Clin Cancer Res. 2004 Jul 1;10(13):4538-49. doi: 10.1158/1078-0432.CCR-04-0037.